P/E at 34.72 vs Industry's 31.39: What the Data Shows for Sun Pharmaceutical Industries Ltd

Valuation Picture: Premium Amidst Sector Norms

The stock’s P/E ratio of 34.72 stands approximately 10.6% above the industry average of 31.39, signalling a valuation premium that investors are currently willing to pay for Sun Pharmaceutical Industries Ltd. This premium suggests expectations of relatively stronger earnings growth or superior business fundamentals compared to peers. However, the premium is not excessively stretched, indicating a balanced market view rather than exuberance. The sector’s P/E itself reflects the pharmaceutical industry’s growth prospects and risk profile, with the company’s valuation aligning with its large-cap status and market leadership.

Performance Across Timeframes: Divergent Momentum

Examining returns across multiple periods reveals a complex momentum profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a positive return of 5.06%, comfortably outperforming the Sensex’s negative 2.92% during the same period. This outperformance extends to longer horizons, with three-year and five-year returns of 81.35% and 191.86% respectively, significantly ahead of the Sensex’s 25.12% and 47.53% gains. However, the 10-year return of 118.45% trails the Sensex’s 192.08%, reflecting a period of relative underperformance in the more distant past.

Shorter-term returns show a more nuanced picture. The stock’s one-month and three-month returns are positive at 2.57% and 3.63%, respectively, while the Sensex has declined by 9.20% and 13.36% over the same periods. Year-to-date, the stock is up 3.67% compared to the Sensex’s 13.39% fall. Yet, the one-week performance shows a slight decline of 0.67%, though still outperforming the Sensex’s 1.95% drop. The one-day gain of 1.45% lags behind the Sensex’s 2.58% rise, indicating some recent underperformance within a generally positive medium-term trend — is this short-term weakness signalling a pause or a deeper correction?

Moving Average Configuration: Mixed Technical Signals

The technical setup of Sun Pharmaceutical Industries Ltd reveals a stock trading above its 50-day, 100-day, and 200-day moving averages, which typically indicates a medium to long-term uptrend. However, it currently trades below its 5-day and 20-day moving averages, suggesting recent short-term selling pressure or consolidation. This configuration often points to a stock in a recovery phase within a broader uptrend, or a temporary pullback after a rally. The proximity to its 52-week high—just 4.72% away—further supports the notion of resilience despite recent volatility.

Sector Performance Context: Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has experienced a mixed performance landscape recently, with a combination of positive, flat, and negative results among constituent stocks. Sun Pharmaceutical Industries Ltd stands out as a large-cap player maintaining relative strength, as evidenced by its outperformance against the Sensex and sector averages over multiple timeframes. The sector’s inherent volatility, driven by regulatory developments, patent expiries, and innovation cycles, continues to influence stock price movements. Against this backdrop, the company’s valuation premium and technical positioning suggest it remains a key bellwether within the industry.

Rating Reassessment: Previously Hold, Now Updated

On 23 Feb 2026, the rating for Sun Pharmaceutical Industries Ltd was updated from a previous Hold rating assigned by MarketsMOJO. This reassessment reflects the evolving fundamentals, valuation, and technical factors analysed. The current Mojo Score stands at 72.0, indicating a positive overall assessment. The rating change invites investors to consider how the updated evaluation aligns with their portfolio strategy — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?

Collective Data Insights: Balancing Valuation and Momentum

The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical stock trading at a reasonable premium to its sector, supported by solid medium-term performance and a mixed but generally constructive technical setup. The divergence between short-term and longer-term returns highlights the importance of timeframe in analysing momentum. The stock’s position above key long-term moving averages but below short-term averages suggests a phase of consolidation or minor correction within an overall uptrend. This nuanced profile is consistent with the recent rating reassessment, which factors in valuation, performance, and technical indicators — what is the current rating for Sun Pharmaceutical Industries Ltd?

Market Capitalisation and Industry Standing

With a market capitalisation of approximately ₹4,27,765.44 crores, Sun Pharmaceutical Industries Ltd is firmly established as a large-cap entity within the Pharmaceuticals & Biotechnology sector. This scale provides it with competitive advantages in research, development, and market reach. The stock’s proximity to its 52-week high, just 4.72% below, underscores its resilience amid sector volatility and broader market fluctuations.

Recent Trading and Relative Strength

On 1 Apr 2026, the stock recorded a 1.45% gain, slightly underperforming the Sensex’s 2.58% rise on the same day. Over the past week, it declined 0.67%, outperforming the Sensex’s 1.95% fall. These short-term moves suggest some profit-taking or sector rotation, but the stock’s relative strength remains intact. The consecutive gain/loss streak data is not explicitly available, but the moving average positioning supports a view of underlying strength despite recent fluctuations.

Conclusion: A Balanced View from the Data

The comprehensive data analysis of Sun Pharmaceutical Industries Ltd reveals a stock that commands a valuation premium justified by its historical outperformance and large-cap stature. The mixed short-term technical signals and recent rating reassessment reflect a dynamic market environment where investors weigh valuation against momentum. The sector’s mixed results further contextualise the stock’s performance, emphasising the importance of a multi-dimensional approach to analysis — is this a moment to hold steady or reconsider exposure?

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today